In this article, we will look at the 8 Best Debt Free Stocks to Buy Right Now.
The market environment has become more complicated following the recent energy shock tied to the Iran conflict, with inflation concerns resurfacing just as expectations for rate cuts were starting to build. BlackRock notes that “The energy shock has further weakened the case for the Fed’s easing rates this year,” while warning of “higher costs, weaker growth, elevated bond yields and more persistent inflation.” At the same time, “Market expectations have flipped from the Fed cutting rates three times this year to veering toward a hike,” suggesting that the path forward for interest rates is no longer as supportive as it once appeared. In that kind of backdrop, balance sheets start to matter more, especially for companies that may have to deal with rising borrowing costs.
That shift is becoming more visible in how institutional investors are framing risk. Franklin Templeton highlights that “Structural leverage and debt burdens are becoming more visible,” with “questions around debt sustainability, refinancing dynamics, and long-duration cash flows” likely to resurface. The firm also stresses the need to “differentiate between liquidity-supported resilience and genuine balance-sheet strength,” pointing toward companies with “strong corporate balance sheets.” This suggests that companies with little to no debt may be better positioned as financing conditions tighten.
Against this backdrop, debt-free companies are starting to stand out not just for stability, but for flexibility. Without the pressure of refinancing or rising interest expenses, these businesses may have more room to navigate volatility and allocate capital more efficiently. With this in mind, we will look at the 8 Best Debt Free Stocks to Buy Right Now.
Our Methodology
We used the Finviz stock screener to identify companies whose enterprise value (EV) is lower than their market capitalization. An EV-to-market-cap ratio of 1.0 or below typically indicates that a company has little to no debt. We then limited our final selection to stocks that have recently reported noteworthy developments likely to influence investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Wheaton Precious Metals Corp. (NYSE:WPM)
On March 18, 2026, Berenberg lowered the price target on Wheaton Precious Metals Corp. (NYSE:WPM) to 13,000 GBp from 13,300 GBp and maintained a Buy rating.
On March 16, 2026, Scotiabank analyst Tanya Jakusconek raised the price target on Wheaton Precious Metals Corp. to $178 from $175 and maintained an Outperform rating following Q4 results. Tanya Jakusconek pointed to the company’s focus on de-risking development assets, advancing studies, and pursuing transactions.
On March 12, 2026, Wheaton Precious Metals Corp. reported Q4 adjusted EPS of $1.22, above the $1.09 consensus estimate, with revenue of $865M compared to $734.98M consensus, while total production reached 205,037 gold equivalent ounces, up from 189,059 a year ago. CEO Randy Smallwood said the company delivered an “outstanding year,” citing results that surpassed production guidance and achieved record revenue, earnings, and operating cash flow, supported by contributions from key assets and ramp-ups across the portfolio. President Haytham Hodaly added that results reflect “disciplined capital allocation,” pointing to portfolio additions and a major streaming transaction announced at Antamina, while expressing confidence in the company’s next phase of growth.
Wheaton Precious Metals Corp. operates as a precious metal streaming company.
7. Franco-Nevada Corporation (NYSE:FNV)
On March 23, 2026, BofA raised the price target on Franco-Nevada Corporation (NYSE:FNV) to $311 from $280 and maintained a Neutral rating, updating its model following Q4 results and guidance.
On March 16, 2026, Scotiabank raised its price target on Franco-Nevada Corporation to $286 from $283 and kept a Sector Perform rating after Q4 results. Scotiabank pointed to the company’s focus on Cobre Panama, advancing studies and permits, and executing on transaction opportunities.
On March 10, 2026, Franco-Nevada Corporation reported Q4 adjusted EPS of $1.85, above the $1.67 consensus estimate, with revenue of $597.3M compared to the $532.77M consensus. The company reported 141,656 GEOs sold, up 18% year over year, and 129,690 net GEOs sold, up 21%. CEO Paul Brink said results reached the “top end” of guidance, driven by a strong fourth quarter, and highlighted higher cash flow supporting a dividend increase and continued capital deployment. Brink added that recent acquisitions add “optional value,” while 2026 guidance and the five-year outlook point to a strong growth foundation, with additional upside tied to exploration activity and a potential restart of Cobre Panama.
Franco-Nevada Corporation operates a royalty and streaming business focused on precious metals and other resources globally.
6. The New York Times Company (NYSE:NYT)
On March 24, 2026, Citi raised the price target on The New York Times Company (NYSE:NYT) to $94 from $77 previously and maintained a Buy rating. Citi described the stock as a “battleground,” noting concerns around missed key performance indicators and an elevated multiple, but said it remains positive on the company’s shift to digital and improving advertising trends.
Last month, The New York Times Company reported Q4 adjusted EPS of 89c, above the 88c consensus estimate, with revenue of $802.31M compared to the $791.55M consensus. The company added about 450,000 net digital-only subscribers during the quarter, bringing total subscribers to 12.78M, while digital-only ARPU rose 0.7% year over year to $9.72, driven by pricing changes and subscriber mix. CEO Meredith Kopit Levien said the quarter capped a “strong year,” pointing to continued execution of strategy and increased value from its news and lifestyle offerings, while expressing confidence in continued growth in subscribers, revenue, profitability, and free cash flow in 2026.
The company expects Q1 total subscription revenues to increase 9%-11%, advertising revenues to rise low-double-digits, and adjusted operating costs to grow 8%-9%.
The New York Times Company creates and distributes news and information globally through The New York Times Group and The Athletic segments.
5. Globus Medical, Inc. (NYSE:GMED)
On March 18, 2026, Wells Fargo assumed coverage of Globus Medical, Inc. (NYSE:GMED) with an Overweight rating and a $104 price target, while maintaining its rating, price target, and estimates.
Last month, Globus Medical, Inc. reported fourth-quarter EPS of $1.28, above the 96c consensus estimate, with revenue of $826.4M compared to the $803.29M consensus. Chief Executive Officer Keith Pfeil said momentum “accelerated in the fourth quarter,” pointing to double-digit sales and earnings growth and expansion across the company’s portfolio, including its spine business, supported by disciplined execution. Pfeil added that the company is focused on sustaining growth through product launches, expanding its sales force, and improving outcomes through its surgical ecosystem.
Globus Medical, Inc. raised its FY26 EPS outlook to $4.40-$4.50 from $4.30-$4.40, above the $4.24 consensus, and expects FY26 revenue of $3.18B-$3.22B compared to the $3.16B consensus.
Globus Medical, Inc. develops and commercializes healthcare solutions for musculoskeletal disorders globally.
4. SentinelOne, Inc. (NYSE:S)
On March 24, 2026, SentinelOne, Inc. (NYSE:S) announced the appointment of Barry Padgett as President and Chief Operating Officer, effective immediately. Barry Padgett previously served as Chief Growth Officer and, most recently, as interim Chief Financial Officer, with the transition coinciding with Sonalee Parekh formally assuming the role of Chief Financial Officer.
On March 23, 2026, SentinelOne, Inc. introduced a new lineup of AI security offerings covering both securing AI systems and using AI to automate security operations. The company said the products build on its existing AI security portfolio, including capabilities to secure autonomous agents and conduct “agentic investigations” with a single click. Among the offerings, Prompt AI Agent Security provides real-time visibility, monitoring, and policy enforcement for AI agents, while Prompt AI Red Teaming enables organizations to simulate attacks and test AI applications. SentinelOne also highlighted new capabilities within its Purple AI system, including “one-click Auto Investigation,” which automates threat analysis and response while maintaining analyst oversight.
On March 12, 2026, SentinelOne, Inc. reported Q4 adjusted EPS of 7c, above the 6c consensus estimate, with revenue of $271.2M compared to the $271.16M consensus. CEO Tomer Weingarten said the company “surpassed the $1 billion revenue milestone,” pointing to 22% year-over-year growth and full-year operating profitability, and added that customers are standardizing on its platform to secure AI and autonomous cybersecurity.
SentinelOne, Inc. provides cybersecurity solutions through its AI-powered platform for threat prevention, detection, and response.
3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
On March 24, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (SNY) announced that Japan’s Ministry of Health, Labour and Welfare approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid. The approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial evaluating Dupixent in adults with the condition.
On March 19, 2026, Wells Fargo raised the price target on Regeneron Pharmaceuticals, Inc. to $825 from $800 and maintained an Equal Weight rating. Wells Fargo said new drugs and mechanisms such as CD20, BAFF/APRILs, and next generation complement inhibitors could expand the generalized Myasthenia Gravis market to $15B in the U.S. and $20B globally by 2036, more than tripling its size, and noted that Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Regeneron could be among the largest beneficiaries, with potential upside to current estimates.
Earlier in March, Barclays initiated coverage on Regeneron Pharmaceuticals, Inc. with an Overweight rating and a $923 price target, saying the stock is “fundamentally mispricing” profits from Dupixent and highlighting pipeline opportunities, including Lynozyfic, along with indication expansion as an “underappreciated tailwind.”
Regeneron Pharmaceuticals, Inc. develops and commercializes medicines across multiple therapeutic areas worldwide.
2. MongoDB, Inc. (NASDAQ:MDB)
On March 24, 2026, MongoDB, Inc. (NASDAQ:MDB) appointed Ryan Mac Ban as Chief Revenue Officer, effective April 27. Ryan Mac Ban brings more than 20 years of experience, most recently serving as Chief Revenue Officer at Confluent, and previously holding senior roles at UiPath, VMware, and Cisco. Outgoing CRO Paul Capombassis will support the transition through Q2.
On March 23, 2026, Mizuho analyst Siti Panigrahi upgraded MongoDB, Inc. to Outperform from Neutral with a price target of $325, up from $290, citing a “compelling” setup following fiscal Q4 results. Siti Panigrahi said the company’s growth profile “has inflected meaningfully,” pointing to fiscal 2026 net customer additions rising 60% year over year, net revenue retention improving from 118% to 121%, and headcount growing just 1% against 23% revenue growth, which signals a shift toward “efficient, durable growth.” Mizuho also highlighted AI as a “structural tailwind,” noting increased application creation and database demand, and views the fiscal 2027 outlook as conservative.
On March 16, 2026, Morgan Stanley lowered its price target on MongoDB, Inc. to $335 from $440 and maintained an Overweight rating, keeping revenue estimates largely unchanged while assuming more gradual margin expansion and applying a lower valuation multiple.
MongoDB, Inc. provides a general-purpose database platform through cloud-based, enterprise, and community offerings.
1. Okta, Inc. (NASDAQ:OKTA)
On March 19, 2026, Macquarie initiated coverage of Okta, Inc. (NASDAQ:OKTA) with an Outperform rating and a $100 price target. Macquarie said the company has “several levers to reaccelerate” remaining performance obligations and revenue growth, pointing to longer-term contracts, go-to-market changes introduced at the start of fiscal 2026, increased engagement with channel partners, and expansion through the AWS Marketplace. The firm also noted potential upside from agentic AI adoption in the identity space and said the shares trade at a discount to cybersecurity peers.
On March 16, 2026, Jefferies maintained a Buy rating and a $105 price target on Okta, Inc. after attending its Okta Showcase 2026 event. Jefferies said identity is becoming more important in an “agentic world,” viewing Okta as a beneficiary, and highlighted tailwinds, go-to-market improvements, and what it described as conservative consensus estimates at 3.5 times expected forward revenue.
Earlier in March, Okta, Inc. reported Q4 EPS of 90c, above the 85c consensus estimate, with revenue of $761M compared to the $749.5M consensus. CEO Todd McKinnon said performance was driven by “continued trust” from large organizations and adoption of new products, reinforcing the company’s identity platform, and added that AI is “redefining the future of software,” increasing the need to secure AI agents, which aligns with Okta’s platform capabilities.
Okta, Inc. provides identity and access management solutions for organizations globally.
READ NEXT: 10 Must-Buy Real Estate Stocks to Invest In and 11 Best High Volume Penny Stocks to Buy Now.
